

DEPRESSIVE SYNDROME BEING THE MASK OF BEGINNING SCHIZOPHRENIC PROCESS - OWN EXPERIENCE

LESZEK TOMASZ ROŚ **

ABSTRACT

Detailed psychiatric examination in my patient demonstrated evident endogenous depressive syndrome and schizoid personality. Besides that, the author, after multiple examinations and numerous visits, diagnosed a beginning schizophrenic process.

Key words: Depression-mask schizophrenic process, impulsive aggression and irritability, sertraline, perphenazine.

In the environment of psychiatrists it is rather commonly known that an episode of "major depression" can, quite not infrequently, be the mask of beginning schizophrenic process. It is known that the highest risk of developing schizophrenia is in the 18 - 25 years age group. If a patient from this age group comes to a psychiatrist with a typical episode of "major depression", it should be always taken into account that this can be a mask of beginning schizophrenic process. Administration of tricyclic antidepressants in such cases may, unfortunately, trigger productive symptoms, that is delusions and hallucinations of schizophrenic psychosis. Therefore, it seems that the safest method in such cases is administration of a neuroleptic with antidepressant action. It seems also

safe to use in such cases an antidepressant from the group of selective serotonin central reuptake inhibitors [31] in combination with a neuroleptic. Some authors [22] demonstrated that sertraline can be here a drug that is safe enough. These authors [22] showed that sertraline is fraught with lower risk of schizophrenic symptom recurrence than imipramine.

Case report

Female patient B.K. aged 22 previously never received any psychiatric treatment. The patient was born after normal pregnancy and labour. Her childhood was moderately good. The patient's parents were apparently warm, considerate, hard working, quiet and affec-

* Central University Teaching Hospital with Polyclinic, Armed Forces School of Medicine Independent Public Health Care Institution

** Adress autora: Leszek Tomasz Ros ul. Zablocinka 6 m, 55 01-697 Warszawa

tive. At home, apparently warm atmosphere was present, full of love and peace. No family rows occurred at home. The order and calm of the family life were only disturbed by small quarrels between the parents. The patient is the only child in the family. Unfortunately, the parents are a type of sado-masochist couple of atypical arrangement of roles. The patient's father had masochist tendencies and the mother - sadistic ones. Reaching of orgasm in both parents was possible only after long initial play including long physical maltreatment. According to the sado-masochist orientation, the mother during the initial play used active aggression against the father in the form of whipping. After such play, they used to have a normal, typical sexual intercourse. This took place during night. The parents fascinated with themselves did not know that the patient, the small girl awoken from sleep, attentively watched these scenes through half-opened door. The patient never told her parents that she was the witness of these scenes. Unfortunately, this caused in her a deep psychic trauma which was the cause of deep aversion to people of either sex. Despite that, she achieved good results in primary and secondary school. The above psychic trauma caused that the patient has been avoiding men until presently. Even the thought that she could have a boyfriend or fiancé, has caused aversion in the patient. Directly after obtaining her secondary school certificate she started to work in order to isolate herself from her peers - other female and male students. In her work she has avoided other people. She has been working as an official in revenue office. She managed to obtain an isolated room in order to work alone and isolated from other people. She has been performing her occupational tasks with moderate success. She has problems with adaptation to reality. Sometimes, for unimportant reasons she was making quarrels with the head of the revenue office. The parents of the patient make all what is possible helping the patient to keep her job.

The patient at the age of 22 years came to the author, referred by her family doctor with the diagnosis of "major depression". Detailed psychiatric examination demonstrated evident endogenous depressive syndrome and schizoid personality with a tendency to development of schizophrenia. Besides that, the author, after multiple examinations and numerous visits, diagnosed a beginning schizophrenic process. The diagnosis was confirmed by tests according to Hamilton Scale, Montgomery-Asberg Scale, SGI Scale, DSM-III-R criteria, and Simpson-Angus Scale and SANS [28, 30, 22, 14, 19, 36, 1]. No mental diseases occurred in patient's family. The patient gave no history of head trauma or loss of consciousness. She denied any serious somatic diseases.

Laboratory tests:

- basic laboratory blood and urine analyses gave normal results
- ECG record was normal,
- EEG record was normal,
- chest radiogram was normal,
- neurological examination: no focal and meningeal symptoms,
- eye fundus examination: normal,
- physical examination was normal,

The intense treatment with individual psychotherapy, oral sertraline in 50 mg daily dose, and perphenazine (Trilafon) in 64 mg daily dose produced complete remission of "major depression" and of the beginning schizophrenic process.

Discussion

A very controversial problem in the described case is the question to what degree the cause of patient's isolation from people and misanthropy are her experiences from childhood. The presence of a causal relationship between patient's experiences from childhood and her later isolation from people and aversion to environment appears quite evident.

Sertraline proved here to be a very favourable drug due to many reasons. The advantage was taken here of doubtless antidepressant effect of sertraline [28, 30, 22, 14, 19, 36, 2, 1, 31]. The patient making quarrels with the head of revenue office due to insignificant reasons, demonstrated impulsive aggression and

irritability. Therefore, the author treating the patient with sertraline took advantage of the experience of other authors [18] who treated with sertraline their patients with personality disturbances with accompanying impulsive aggression and irritability. These authors [18] achieved a satisfactory therapeutic result.

REFERENCES

- [1] *Authors:*
Aguglia E., Casacchia M., Cassano G.B.
Institution:
University of Trieste, Italy
Title:
Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
Porównanie skuteczności i bezpieczeństwa stosowania sertraliny i fluoksetyny w leczeniu dużej depresji, badanie z wykorzystaniem podwójnie ślepej próby.
Source
International Clinical Psychopharmacology. 8(3): 197-202, 1993 Fall
- [2] *Authors:*
Bennie E.H., Mullin J.M., Martindale J.J.
Institution:
Leverndale Hospital, Glasgow, UK
Title:
A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
Porównanie fluoksetyny i sertraliny w grupie chorych z dużą depresją leczonych ambulatoryjnie, badanie wieloośrodkowe z wykorzystaniem metody podwójnie ślepej.
Source
Journal of Clinical Psychiatry. 56 (6): 229-37, 1995 Jun.
- [3] *Authors:*
Beshay H., Pumarega A.J.
Institution:
James H. Quillen College of Medicine, East Tennessee State University, Quillen/Mountain Home Veterans Administration Medical Center, Johnson City 37684, USA
Title:
Sertraline treatment of mood disorder associated with prednisone: a case report.
Leczenie zaburzeń nastroju występujących podczas podawania prednisonu przy pomocy sertraliny.
Source:
Journal of Child and Adolescent Psychopharmacology. 8 (3): 187-93, 1998
- [4] *Authors:*
Biri H., Isen K., Sinik Z.
Institution:
Department of Urology, Medical School of Gazi University, Ankara, Turkey
Title:
Sertraline in the treatment of premature ejaculation: a double-blind placebo-controlled study.
Skuteczność sertraliny w leczeniu przed-

- wczesnego wytrysku: badania metodą podwójnej ślepej próby z wykorzystaniem grupy kontrolnej placebo.
Source:
 International Urology and Nephrology, 30 (5): 611-5, 1998
- [5] *Authors:*
 Brady K.I., Sonne S.C., Roberts J.M.
Institution:
 Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29426, USA
Title:
 Sertraline treatment of comorbid post-traumatic stress disorder and alcohol dependence.
 Leczenie sertralina w przypadku współwystępowania zespołu stresu pourazowego i uzależnienia od alkoholu.
Source:
 Journal of Clinical Psychiatry. 56 (11): 502-5, 1995 Nov.
- [6] *Authors:*
 Chouinard G.
Institution:
 Department of Psychiatry, University of Montreal, Hospital Louis H. Lafontaine, Quebec, Canada
Title:
 Sertraline in the treatment of obsessive-compulsive disorder: two double-blind, placebo-controlled studies. [Review] [40 refs]
 Leczenie zespołu obsesyjno-kompulsyjnego przy użyciu sertraliny: badanie z użyciem podwójnie ślepej próby i kontroli placebo.
Source:
 International Clinical Psychopharmacology. 7 Suppl. 2: 37-41, 1992 Oct.
- [7] *Authors:*
 Croft H., Settle E.Jr., Houser T.
Institution:
 Charleston Area Medical Center, West Virginia, USA
Title:
 A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropione and sertraline.
 Porównanie skuteczności działania przeciwdepresyjnego i wpływu na funkcje seksualne bupropionu o przedłużonym uwalnianiu i sertraliny, badanie z użyciem kontroli placebo.
Source:
 Clinical Therapeutics. 21 (4): 643-58, 1999 Apr.
- [8] *Authors:*
 Davis S.M., Harrison W.M., Keller M.B.
Institution:
 Rhode Island Hospital and Brown University, Providence 02903, USA
Title:
 The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.
 Leczenie przewlekłej depresji część 3: funkcjonowanie psychospołeczne przed leczeniem sertralina lub imipramina i po jego zakończeniu.
Source:
 Journal of Clinical Psychiatry. 59 (11): 608-19, 1998 Nov.
- [9] *Authors:*
 Ekselius L., von Knorring L.
Institution:
 Department of Neuroscience, Psychiatry, University Hospital, Uppsala, Sweden
Title:
 Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.
 Zaburzenia osobowości współwystępujące z dużą depresją a skuteczność leczenia sertralina lub citalopramem.
Source:

- [10] *Authors:*
Finkel S.L., Richter E.M., Clary C.M.
Institution:
Northwestern University Medical School,
Department of Psychiatry and Behavioral
Sciences, Chicago, IL 60611-3317, USA
Title:
Comparative efficiency and safety of
sertraline versus nortriptyline in major
depression in patients 70 and older.
Porównanie skuteczności i bezpieczeństwa
sertraliny i nortryptyliny w grupie chorych
w wieku 70 i więcej lat.
Source:
International Psychogeriatrics. 11 (1): 85-
99, 1999 Mar.
- [11] *Authors:*
Griest J., Chouinard B., DuBoff B.
Institution:
Dean Foundation for Health, Research,
and Education, Madison, Wis., USA
Title:
Double-blind parallel comparison of
three dosages of sertraline and placebo
in outpatients with obsessive-compulsive
disorder.
Porównanie trzech dawek sertraliny i pla-
cebo w leczeniu ambulatoryjnym chorych
z zespołem obsesyjno-kompulsyjnym; ba-
dania z użyciem podwójnie ślepej próby.
Source:
Archives of General Psychiatry. 52 (4):
289-96, 1995 Apr.-
- [12] *Authors:*
Greist J.H., Jefferson J.W., Kobak K.A.
Institution:
Dean Foundation for Health, Research and
Education, Madison, WJ 53/17, USA
Title:
A 1 year double-blind placebo-controlled
fixed dose study of sertraline in the treat-
ment of obsessive-compulsive disorder.
Trwające rok badanie skuteczności sertra-
liny stosowanej w stałej dawce, w leczeniu
zespołu obsesyjno-kompulsyjnego, z
wykorzystaniem podwójnie ślepej próby
i kontroli placebo.
Source:
International Clinical Psychopharmacology. 10 (2): 57-65, 1995 Jun.
- [13] *Authors:*
Grignaschi G., Samanin R.
Institution:
Istituto di Ricerche Farmacologiche
Mario Negri, Milan, Italy
Title:
Role of serotonin receptors in the effects
of sertraline on feeding behaviour.
Wpływ sertraliny na zachowanie związane
z przyjmowaniem pokarmów - rola recep-
torów serotoninowych.
Source:
Psychopharmacology. 110 (1-2): 203-8,
1993
- [14] *Authors:*
Hirschfeld R.M., Russell J.M., Delgado
P.L.
Institution:
Department of Psychiatry and Behavioral
Sciences, University of Texas Medical
Branch at Galveston 77555-0429, USA
Title:
Predictors of response to acute treatment
of chronic and double depression with
sertraline or imipramine.
Czynniki pozwalające na przewidywanie
reakcji na ostrą fazę leczenia sertralina
lub imipraminą u chorych z przewlekłą
lub podwójną depresją.
Source:
Journal of Clinical Psychiatry. 59 (12):
669-75, 1998 Dec.
- [15] *Authors:*
Jermain D.M., Preece C.K., Syles R.L.
Institution:
Department of Pharmacy, Scott and White
Memorial Hospital, Temple, Tex., USA
Title:
Luteal phase sertraline treatment for

- premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, cross-over study.
 Podawanie sertraliny w fazie lutealnej cyklu w leczeniu zespołu dysforii przedmiesiączkowej. Wyniki krzyżowego badania z wykorzystaniem podwójnie ślepej próby i kontroli placebo.
Source:
 Archives of Family Medicine. 8 (4): 328-32. 1999 Jul-Aug.
- [16] *Authors:*
 Kant R., Smith-Seemiller L., Zeiler D.
Institution:
 Head Injury Clinic, St. Francis Medical Center, Pittsburgh, PA 15524, USA
Title:
 Treatment of aggression and irritability after head injury.
 Leczenie agresji i drażliwości u osób, które doznały urazu głowy.
Source:
 Brain Injury. 12 (8): 661-6, 1998 Aug.
- [17] *Authors:*
 Katzelnick D.J., Kobak K.A., Greist J.H.
Institution:
 Foundation for Health, Research and Education, Madison, WJ 53/17, USA
Title:
 Sertraline for social phobia: a double-blind, placebo-controlled cross-over study.
 Leczenie fobii społecznej przy użyciu sertraliny, krzyżowe badanie z użyciem podwójnie ślepej próby i kontroli placebo.
Source:
 American Journal of Psychiatry. 152 (9): 1368-71, 1995 Sep.
- [18] *Authors:*
 Kavoussi R.J., Coccaro E.F.
Institution:
 Department of Psychiatry, Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129
Title:
 An open trial of sertraline in personality disorder in patients with impulsive aggression. Otwarte badania sertraliny u pacjentów z zaburzeniami osobowości z towarzyszącą impulsywną agresją.
Source:
 Journal of Clinical Psychiatry. 55 (4): 137-41, 1994 Apr.
- [19] *Authors:*
 Keller M.B., Gelenberg A.J., Hirschfeld R.M.
Institution:
 Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, RI 02912, USA
Title:
 The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.
 Leczenie przewlekłej depresji część 2: porównanie skuteczności sertraliny i imipraminy z wykorzystaniem podwójnie ślepej próby i losowym podziałem na grupy.
Source:
 Journal of Clinical Psychiatry. 59 (11): 598-607, 1998 Nov.
- [20] *Authors:*
 Keller M.B., Harrision W., Fawcett J.A.
Institution:
 Butler Hospital, Brown University, Providence, RI 02912, USA
Title:
 Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community.
 Leczenie przewlekłej depresji sertralina lub imipraminą: wstępne dane dotyczące odsetka reakcji oraz duża częstość nieodpowiedniego leczenia w warunkach podstawowej opieki medycznej.
Source:

- Psychopharmacology Bulletin. 31 (2): 205-12, 1995
- [21] *Authors:*
Keller M.B., Kocsis J.H., Thase M.
Institution:
Department of Psychiatry, Butler Hospital, Brown University, Providence, RJ 02906, USA
Title:
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
Skuteczność podtrzymującego leczenia sertralina u chorych z depresją przewlekłą: badania kontrolowane z losowym podziałem na grupy.
Source:
JAMA. 280 (19): 1665-72, 1998 Nov 18
- [22] *Authors:*
Kirli S., Caliskan M.
Institution:
Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey
Title:
A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia.
Porównawcze badania sertraliny i imipraminy w leczeniu depresji popsychotycznej u chorych na schizofrenię.
Source:
Schizophrenia research. 33 (1-2), 1998 Sep 7
- [23] *Authors:*
Kroning M.H., Apter J., Asnis G.
Institution:
Department of Psychiatry, Millside Hospital of LIJMC, Glen Oaks, New York, USA
Title:
Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
Wieloośrodkowe badanie skuteczności leczenia zespołu natręctw przy użyciu sertraliny z wykorzystaniem kontroli placebo.
Source:
Journal of Clinical Psychopharmacology. 19 (2): 172-6, 1999 Apr.
- [24] *Authors:*
Lambert M.T., Trutia C, Petty F.
Title:
Extrapyramidal adverse effects associated with sertraline.
Pozapiramidowe objawy niepożądane związane ze stosowaniem sertraliny.
Source:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22 (5): 741-8, 1998 Jul.
- [25] *Authors:*
Lauterbach E.C.
Institution:
Department of Psychiatry and Behavioral Sciences, Mercer University School of Medicine, Macon, Georgia, USA
Title:
Catatonia - like events after valproic acid with risperidone and sertraline.
Wystąpienie objawów o typie katatonii po łącznym podaniu kwasu walproinowego, risperidonu i sertraliny.
Source:
Neuropsychiatry, Neuropsychology and Behavioral Neurology. 11 (3): 157-63, 1998 Jul
- [26] *Authors:*
Levin L.D., Briggs S.J., Christopher N.C.
Institution:
Department of Psychiatry, Duke University, Durham, NC 27710
Title:
Sertraline attenuates hyperphagia in rats following nicotine withdrawal.
Sertralina hamuje nadmierny apetyt u szczurów, którym odstawiono nikotynę.
Source:

- Pharmacology, Biochemistry and Behavior, 44 (1): 51-61, 1993 Jan.
- [27] *Authors:*
Londborg P.D., Wokow R., Smith W.T.
Institution:
Summit Research Network, Seattle, Washington 98104, USA
Title:
Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation.
Leczenie zespołu lęku napadowego przy użyciu sertraliny. Badanie wielośrodkowe z wykorzystaniem podwójnie ślepej próby, kontroli placebo i stałej dawki leku.
Source:
British Journal of Psychiatry. 173: 54-60, 1998 Jul.
- [28] *Authors:*
Luketso G.G., Taragano F., Freisman G.J.
Institution:
Neuropsychiatry and Memory Group, John Hopkins University, Baltimore, MD, USA
Title:
Major depression and its response to sertraline in primary care vs. Psychiatric office practice patients, results of an open-label trial in Argentina.
Leczenie dużej depresji przy pomocy sertraliny - porównanie wyników uzyskiwanych w praktyce ogólnej oraz w poradniach psychiatrycznych. Wyniki badania otwartego przeprowadzonego w Argentynie.
- [29] *Authors:*
McMahon D.G.
Institution:
St. Luke's Hospital Complex, Sydney, Austria
Title:
Treatment of premature ejaculation with sertraline hydrochloride.
Leczenie przedwczesnego wytrysku przy pomocy chlorowodoru sertraliny.
Source:
International Journal of Impotence Research. 10 (3): 181-4, discussion 185, 1998 Sep.
- [30] *Authors:*
Moller H.J., Gallinat J., Hegerl U.
Institution:
Psychiatric Hospital, Ludwig Maximilians University, Munich, Germany
Title:
Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression.
Porównanie skuteczności sertraliny i amitriptyliny w grupie hospitalizowanych chorych z dużą depresją, badanie wielośrodkowe, z wykorzystaniem metody podwójnie ślepej próby.
Source:
Pharmacopsychiatry. 31 (6): 170-7, 1998 Sep.
- [31] *Authors:*
Murdoch D., McTavish D.
Institution:
Adis International Limited, Auckland, New Zealand
Title:
Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive compulsive disorder. [Review][72 refs]
Sertralina. Przegląd właściwości farmakologicznych i farmakokinetycznych oraz skuteczność w leczeniu depresji i zespołu obsesyjno-kompulsyjnego.
Source:
Drugs. 44 (4): 604-24, 1992 Oct.
- [32] *Authors:*
Oinan T.G.
Institution:

- Department of Psychological Medicine, St. Bartholomew's Hospital, London, United Kingdom
Title:
 Lithium augmentation in sertraline - resistant depression: a preliminary dose - response study.
 Dołączenie kuracji litem u chorych z depresją oporną na leczenie sertralina; wstępne badanie związku reakcji z dawką.
Source:
 Psychiatrica Scandinavica. 88 (4): 300-1, 1993 Oct.
- [33] *Authors:*
 Pollack M.H., Otto M.W., Wortington J.J.
Institution:
 Anxiety Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114-3117, USA
Title:
 Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
 Sertralina w leczeniu zespołu lęku napadowego: badanie wieloośrodkowe z użyciem zmiennych dawek.
Source:
 Archives of General Psychiatry. 55 (11): 1010-6, 1998 Nov.
- [34] *Authors:*
 Preskorn S.H., Lane R.M.
Institution:
 Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita 67214, USA
Title:
 Sertraline 50 mg daily: the optimal dose in the treatment of depression. [Review] [55 refs]
 Sertralina w dawce 50 mg/d: optymalna dawka w leczeniu depresji.
Source:
 International Clinical Psychopharmacology. 10 (3): 129-41, 1996 Sep.
- [35] *Authors:*
 Roy A.
Institution:
 Psychiatry Service, Department of Veterans Affairs Medical Center, East Orange, NJ 07019, USA
Title:
 Placebo - controlled study of sertraline in depressed recently abstinent alcoholics.
 Ocena skuteczności sertraliny w grupie osób od niedawna zachowujących abstynencję od alkoholu; badanie z wykorzystaniem grupy kontrolnej placebo.
Source:
 Biological Psychiatry. 44 (7): 633-6, 1998 Oct 1
- [36] *Authors:*
 Rush A.J., Koran L.M., Keller M.B.
Institution:
 Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75235-9086, USA
Title:
 The treatment of chronic depression, part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation and maintenance phase therapies.
 Leczenie depresji przewlekłej, część 1: plan badania i uzasadnienie porównawczej oceny skuteczności sertraliny i imipraminy jako kuracji ostrych, kontynuowanych i podtrzymujących.
Source:
 Journal of Clinical Psychiatry. 59 (11): 589-97, 1998 Nov.
- [37] *Authors:*
 Shapiro P.A., Lesperance F., Frasure-Smith N.
Institution:
 Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Title:
 An open-label preliminary trial of sertrali-

ne for treatment of major depression after acute myocardial infarction.

Otwarte, wstępne badanie skuteczności sertraliny w leczeniu dużej depresji u chorych po ostrym zawale mięśnia sercowego.

- [38] *Authors:*
Turner R.
Institution:
Pfizer Central Research, Groton, CT
Title:
Quality of life: experience with sertraline.
Jakość życia: doświadczenia z sertralina.
Source:
International Clinical Psychopharmacology. 9 Suppl 3: 27-31, 1994 Jun.

- [39] *Authors:*
Turner R.
Institution:

USC-LAC Medical Center 90033, USA

Title:

Sertraline in social phobia.

Sertralina w fobii społecznej

Source:

Anxiety. 1(4): 196-8, 1994-95

- [40] *Authors:*
Wadden T.A. Bartlett S.J., Foster G.D.
Institution:
Dept. of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Title:
Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial.
Sertralina i trening zapobiegania nawrotom stosowane po leczeniu przy pomocy diety o bardzo małej zawartości kalorii: kontrolowana próba kliniczna.
Source:
Obesity Research. 3 (6): 549-57, 1995 Nov.